← Leaderboards
Bill H Chang
Oregon Health & Science University
$918,328
Attributed
$1,783,164
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $352.3K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,783,164 · 2
By mechanism
R01$1,729,672 · 1
F32$53,492 · 1
Top collaborators
- Jeffrey Wallace Tyner5 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jeffrey Wallace Tyner$13,872,769
- Anupriya Agarwal$8,829,719
- George Victor Thomas$5,625,841
- Haijiao Zhang$1,696,427
- Stephen E Kurtz$864,836
Others in their field
Top investigators on “Foundations”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Mitchell J Malone · Texas A&M Research Foundation$353,400,900
- Gary D Acton · University Of California-Davis$320,373,312
- George R Seage · Abt Associates, Inc.$281,069,277
- Everette D Joseph · Howard University$268,880,223
- Valerie Koch · University Corporation For Atmospheric Res$265,601,376
Research focus
FoundationsHematologic NeoplasmsEvaluationAcute Myeloid Leukemia CellBiochemicalAdaptor Signaling ProteinAcute Myelocytic LeukemiaBone Marrow CellsCell KillingCell LineCell ModelCellsCell SurvivalBiochemical PathwayBiological ModelsAnimal ModelClinical DevelopmentCombined Modality TherapyComplexCrispr/Cas TechnologyDependenceDrug CombinationsEffective TherapyHematology
Grant awards (6)
Targeting PTPN11 dependent Hematologic Malignancies$334,662
R01 · FY2024 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$345,230
R01 · FY2023 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$345,230
R01 · FY2022 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$352,275
R01 · FY2021 · CA · contact PI
Targeting PTPN11 dependent Hematologic Malignancies$352,275
R01 · FY2020 · CA · contact PI
Aurora B kinase is the downstream target of ATR$53,492
F32 · FY2005 · GM